Bioequivalence Clinical Trial
— CHILD-IVITABOfficial title:
Single-center, Open-label, Randomized, Two-period, Two-way Crossover Study to Investigate the Bioequivalence of a Single-dose of 12 mg IVERMECTIN Administered as Orally Disintegrating Mini Tablets (CHILD-IVITAB) Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets (STROMECTOL) in Healthy Adults Under Fasting Conditions
Verified date | December 2022 |
Source | University Children's Hospital Basel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I, single-center, open-label, randomized, two-period, two-way crossover, single-dose bioequivalence study in which the active substance ivermectin is administered as a single dose of 12 mg as either CHILD-IVITAB or STROMECTOL during two study drug administration periods. Each treatment will be investigated in the same subgroup of 16 healthy male or female study participants under fasted conditions.
Status | Completed |
Enrollment | 16 |
Est. completion date | December 15, 2022 |
Est. primary completion date | December 15, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Male or female aged between 18 and 45 years (inclusive) at screening. - Healthy adult females on contraceptives at least 1 month prior to the start of the study until 1 month after the completion of the study and urine pregnancy test at screening and pre-study drug administration negative. - No history of alcohol or drug abuse. - No history of chronic liver or kidney disease. - No clinically significant findings on the physical examination at screening. - Body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening. - Normal blood pressure and heart rate (Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and heart rate (HR) 45-90 bpm (inclusive), measured after 5 minutes in the supine position at screening). - Hematology and blood chemistry results not deviating from the normal range to a clinically relevant extent at screening. Gilbert's syndrome (increased total and unconjugated bilirubin when fasting) will be accepted if mild. - A 12-lead ECG without significant abnormalities (QTc ³450 msec at screening or pronounced sinus bradycardia (<40 bpm/min), even if elicited by sport) - Negative urine drug screen (amphetamines, benzodiazepines, cannabis, cocaine, and opiates). - Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study. - The participant agrees to be available for scheduled visits. - Informed and signed consent obtained prior to any study-mandated procedure (including specific request for HIV serology and hepatitis as well as for urinary screen for drugs). Exclusion Criteria: - Eligible participants must meet none of the following exclusion criteria: - Known hypersensitivity to any excipients of the drug formulations. - Treatment with another investigational drug within 3 months prior to screening. - Participation in a clinical study/trial in the previous 3 months unless no treatment taken or large amounts of blood collected - History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. - Significant caffeine consumption defined as > 400 mg per day at screening. - History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug. - History of moderate or severe allergy or asthma at any time. Allergic rhinitis is acceptable if non symptomatic when starting the study and if symptoms are not anticipated to occur during the first 4 weeks of each period and are not expected to require a corticosteroid treatment. - History of cardiovascular dysfunction if considered as clinically relevant (conduction abnormality, arrhythmia, bradycardia, angina pectoris, cardiac hypertrophy unless elicited by training, embolism). - Recurrent hypotensive events considered as clinically relevant. - Intense sport activities up to 4 days before inclusion - Use of any medication the week prior to study or as based on 5 plasma half-life rule (before screening, after screening) and throughout study. Paracetamol is permissible before the study as a rescue medication but only with investigator's permission. - Smoking (consumption of =5 cigarettes/day or equivalent is acceptable, provided the subject commits to quit entirely during the study) - Loss of 350 ml or more of blood or blood donation within 3 months prior to screening. - Positive results from the hepatitis serology, except for vaccinated (hepatitis B virus) participants, at screening. - Positive results from the HIV serology at screening. - Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. - Legal incapacity or limited legal capacity at screening. l |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital CHUV, Service of Clinical Pharmacology | Lausanne |
Lead Sponsor | Collaborator |
---|---|
University Children's Hospital Basel | Galvita AG, Switzerland, Permamed AG, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pharmacokinetics (PK) primary endpoint | Change in the area under the plasma concentration-time curve from zero to infinity (AUC0-8) of ivermectin in each treatment period | At Baseline, at 30 and 60 minutes, at 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 and 96 hours after study drug administration in each treatment period | |
Secondary | The maximum plasma concentration (Cmax) of ivermectin in each treatment period | The maximum plasma concentration (Cmax) of ivermectin in each treatment period | Over a time period of 11 hours after study drug administration in each treatment period | |
Secondary | The area under the plasma concentration-time curve from time zero to time t of the last measured concentration above the limit of quantification (AUC0-tlast) of ivermectin in each treatment period | The area under the plasma concentration-time curve from time zero to time t of the last measured concentration above the limit of quantification (AUC0-tlast) of ivermectin in each treatment period | Over a time period of 11 hours after study drug administration in each treatment period | |
Secondary | The time to reach maximum plasma concentration (tmax) of ivermectin in each treatment period | The time to reach maximum plasma concentration (tmax) of ivermectin in each treatment period | Over a time period of 11 hours after study drug administration in each treatment period | |
Secondary | Supine blood pressure (systolic and diastolic) | Change from baseline to each time point of measurement during each treatment period as per study schedule for supine blood pressure | At Baseline, at 2, 4, 24, 48, 72 and 96 hours after study drug administration in each treatment period and at Day 7-10 of period 2 | |
Secondary | ECG (conduction changes) | Change from baseline to each time point of measurement during each treatment period as per study schedule for ECG variables (conduction system) | At Baseline, at 2, 4 hours after study drug administration in each treatment period and at Day 7-10 of period 2 | |
Secondary | Adverse events (AEs) reporting from first drug administration up to end of study (EOS) (number of AEs) | Adverse events (AEs) reporting from first drug administration up to EOS | From Baseline until Day 7-10 of period 2 (between 4 to a maximum of 7 weeks) | |
Secondary | Tolerability of Treatments A and B utilizing a visual analogue scale (VAS) for gastrointestinal tract (GIT) (2 items) | Tolerability of Treatments A and B utilizing a VAS for GIT (2 items) ; (0 = tolerable; 10 = very untolerable) | At Baseline, at 30 and 60 minutes, at 2, 3, 4, 6, 10 hours after study drug administration in each treatment period | |
Secondary | Tolerability of Treatments A and B utilizing a VAS for central nervous system (CNS) (6 items) | Tolerability of Treatments A and B utilizing a VAS for CNS (6 items); (0 = tolerable; 10 = very untolerable) | At Baseline, at 30 and 60 minutes, at 2, 3, 4, 6, 10 hours after study drug administration in each treatment period | |
Secondary | Palatability of Treatments A and B utilizing a VAS (bitterness, sweetness, intensity, and palatability/acceptability) | Palatability of Treatments A and B utilizing a VAS (bitterness, sweetness, intensity, and palatability/acceptability); (0 = pleasant; 10 = very unpleasant) | At 0 and at 30 minutes after study drug administration in each treatment period | |
Secondary | Heart rate | Change from baseline to each time point of measurement during each treatment period as per study schedule for Heart rate | At Baseline, at 2, 4, 24, 48, 72 and 96 hours after study drug administration in each treatment period and at Day 7-10 of period 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03705533 -
Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State
|
Phase 1 | |
Completed |
NCT04938856 -
Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03646331 -
Bioequivalence of Imeglimin Tablet Formulations
|
Phase 1 | |
Completed |
NCT04564456 -
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05197517 -
Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition
|
Phase 1 | |
Completed |
NCT03702894 -
Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Withdrawn |
NCT02894515 -
Bioequivalence Study of Idalopirdine in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03018015 -
Ibuprofen Bioavailability Trial With Oral Single Dose Administration.
|
Phase 1 | |
Completed |
NCT02206295 -
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
|
Phase 1 | |
Completed |
NCT01331993 -
A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
|
Phase 1 | |
Completed |
NCT01260805 -
A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
|
Phase 1 | |
Recruiting |
NCT06066112 -
Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body
|
Phase 1 | |
Completed |
NCT04546256 -
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05083325 -
Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product
|
Phase 1 | |
Completed |
NCT05061901 -
Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT04138888 -
A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT05145621 -
Oral Bio-equivalence Study
|
Phase 1 | |
Completed |
NCT06124560 -
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
|
Phase 1 | |
Completed |
NCT03340753 -
Bioavailability of KBP-5074 Tablet vs Capsule Formulations
|
Phase 1 | |
Completed |
NCT04230070 -
Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product
|
Phase 1 |